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Abstract
The role that androgens play in mediating elevated blood pressure is unclear. Low levels of androgens in men and increased levels of androgens in women, as occurs with polycystic ovary syndrome (PCOS), are both associated with increased risk for cardiovascular disease and elevated blood pressure. We have used animal models to evaluate the potential mechanisms by which men and women have differential responses to androgens that affect regulation of blood pressure and the implications these may have for the health of men and women. T he role that androgens play in mediating elevated blood pressure is unclear. Low levels of androgens in men are associated with obesity and cardiovascular disease. 1, 2 In contrast, in women, elevated levels of androgens cause polycystic ovary syndrome (PCOS) that is also characterized by increased body weight and characteristics of cardiovascular disease. 3, 4 We have used animal models to evaluate the potential mechanisms by which men and women have differential responses to androgens that affect regulation of blood pressure and the implications these may have for the health of men and women.
ANDROGENS IN MEN
Reductions in androgens are a common finding in men who are overweight or obese. 1, 2, 5, 6 In fact, all chronic diseases, such as chronic kidney disease, cancers, and atherosclerosclerosis, are associated with reductions in serum androgens in men. Whether the reduction in androgens is a cause or a consequence of chronic disease states such as obesity and metabolic syndrome is not known, as there have been no serial studies in men to determine if reductions in androgens predated the development of a chronic disease. However, favoring the "consequence" concept, one could imagine that, teleologically, the presence of chronic disease in men may cause a reduction in androgen levels to prevent procreation and thus protect the species ("survival of the fittest"). Alternatively, a reduction in androgens could be a risk factor for development of chronic disease, and, in fact, reductions in androgens are associated with reduced longevity, risk of fatal cardiovascular events, sarcopenia, osteoporosis, frailty, cognitive impairment, depression, sleep apnea, and atrial fibrillation. 7 In any case, androgen supplements are becoming commonplace in obese men.
ANDROGENS AND MALE OBESE ZUCKER RATS (OZR)
Male OZR (fa/fa) are a model of leptin receptor deficiency that is characterized by massive obesity. The control rats are the lean litter mates (LZR) (FA/FA). Male OZR are nonreproductive, and we showed several years ago that OZR have serum total testosterone levels that are approximately 30% of the levels found in male LZR. 8 We tested the hypothesis that if testosterone was increased in OZR to levels similar to or higher than LZR, that would cause renal injury and subsequent hypertension. Thus, at 22 weeks of age, a time when blood pressure was not elevated, rats were implanted with testosterone-containing silastic pellets that increased serum total testosterone by 10-fold in both OZR and LZR. 8 Rats were treated for 10 weeks. In OZR, testosterone levels were approximately 4-fold higher than in control LZR. We were very surprised by the outcome of these studies. Tenfold increases in testosterone in the LZR was associated with increased albuminuria and proteinuria, increased glomerular sclerosis but no changes in body weight, plasma cholesterol, leptin, or insulin. 8 Testosterone supplements also had no effect on blood pressure in the LZR.
In contrast, in the OZR, testosterone supplements caused a >200-g reduction in body weight that was caused in part by increased activity. 8 In addition, plasma insulin, cholesterol, and leptin were reduced, along with the area under the curve for oral glucose tolerance test (OGTT), thus attenuating the symptoms of metabolic syndrome. Proteinuria and albuminuria were also reduced in the OZR, and there was no change in the glomerular injury compared with untreated OZR. By 32 weeks of age, there was an age-related increase in blood pressure in OZR, and unlike in the LZR, testosterone supplements caused a significant increase in blood pressure in the OZR. 8 We concluded from these studies that androgen supplements in obese men could be protective against metabolic syndrome but that blood pressure needed to be monitored closely. A meta-analysis that included 32 of 824 retrieved articles that included the terms body composition and testosterone in obese men, aged 51.7AE6.1 years, showed testosterone supplements improved insulin resistance, reduced body fat and increased lean mass, and improved lipid profiles. 9 The meta-analysis data also supported a reduction in blood pressure with testosterone supplements. Perhaps the difference between our study in the rats and those of the meta-analysis was the age-related increase in blood pressure in the control OZR that influenced the further increase in blood pressure with testosterone supplements.
Our data do not provide mechanisms by which chronic androgens increase blood pressure in the OZR. We have data that conversion of testosterone to estradiol may actually provide some protection against even higher blood pressure with androgens in the OZR, as anastrozoledthe inhibitor of the conversion of testosterone to estradiold in testosterone-treated OZR causes further increases in their blood pressure (Reckelhoff, unpublished data). Other mechanisms will be studied in the future.
ANDROGENS IN WOMEN
Polycystic ovary syndrome (PCOS) is the most common endocrine abnormality in reproductive-aged women, and symptoms can occur as early as menarche. 10 One of the defining symptoms of PCOS is hyperandrogenemia, but PCOS is also characterized in many women by overweight or obesity, hyperlipidemia and metabolic syndrome, and elevated blood pressure. 4, 11, 12 Typically, the elevated blood pressure does not meet the guidelines for antihypertensive treatment but is still elevated for young women compared with controls. 4 Several years ago, Manneras and colleagues developed a model of PCOS in female rats by administering long-term dihydrotestosterone (DHT), beginning prepubertally. 13 DHT was used rather than testosterone, as DHT is not converted to estradiol. They used the DHT-treated female animal model of PCOS to evaluate the gynecological consequences of increased androgens. 13 We adopted this animal model to determine the cardiovascular and renal implications of androgens in female rats.
As in the Manneras model, female rats were implanted with DHT pellets at approximately 4 weeks of age and increased serum DHT levels by 3-to 4-fold, 4 which is typical for women with PCOS. 12 It should be noted that the levels of DHT developed by the supplements are 20-fold lower than would be found in men. Furthermore, the levels of DHT are not sufficient to cause downregulation of endogenous sex steroids, so serum testosterone and estradiol levels in the model are not affected. 4 DHT caused a sustained increase in food intake of 3 grams per day in the model, and this led to an increase in body weight and an increase in subcutaneous fat but not visceral fat, as determined by computed tomography. Along with the increase in body weight, the DHT-treated female rats developed hypercholesterolemia, hyperinsulinemia, hyperleptinemia, and increase in OGTT. Note that these effects are opposite of the effects that androgens had in male OZR or LZR. What was similar between the male and female rats treated with androgens was the increase in blood pressure. Both male and female rats given androgens experienced sustained increases in blood pressure. 4, 8 
MECHANISMS RESPONSIBLE FOR HYPERTENSION IN HYPERANDROGENEMIC FEMALE RATS
Role of the Sympathetic Nervous System and Melanocortin-4 Receptor The sympathetic nervous system (SNS) has been shown by numerous investigators to play a role in mediating hypertension in obese animal models. [14] [15] [16] In the hyperandrogenemic female rat model, we tested whether blockade of the adrenergic receptors would affect blood pressure. We found that hyperandrogenemic female rats treated with terazocin and propranolol, a1-and b1,2-adrenergic receptor antagonists, had greater reductions in blood pressure than did control female rats. 17 These data supported the role for the SNS in mediating the elevated blood pressure with DHT. Similarly, we found that renal denervation prevented the androgens from increasing the blood pressure in the female rats, 17 suggesting that the SNS was working through the renal nerves to increase the blood pressure in the female rats in response to androgens.
The mechanism by which the SNS was activated in the hyperandrogenic female rat model was not clear from these data, however. One mechanism for activation of the SNS is due to activation of melanocortin-4 receptor (MC4R). 15, 17 Leptin and other mediators are thought to increase expression of a-MSH, which, in turn, binds to MC4R in the pro-opiomelanocortin (POMC) neurons of the hypothalamus. Activation of the MC4R mediates satiety and causes an increase in sympathetic activity. 18 Thus, if animals or humans develop leptin resistance or have leptin-receptor deficiency, as in the OZR, satiety is not reached when leptin is increased, and food consumption is increased compared with controls. In addition to food intake, MC4R activation causes an increase in sympathetic activity that can also affect thermoregulation and cause an increase in blood pressure. 19 Several years ago, Da Silva and colleagues reported that blockade of MC4R with an antagonist, SHU-9119, caused a reduction in blood pressure in male spontaneously hypertensive rats (SHR), 20 a model of essential hypertension in which it is well known that sympathetic activation contributes to the hypertension. 21 We thus tested the hypothesis that the sympathetic activation in hyperandrogenemic female rats was mediated by activation of the MC4R. 17 DHT-treated female rats were given SHU-9119 intracerebroventricularly. Food intake increased considerably in both DHTtreated and control female rats, an indicator that the MC4R was indeed blocked. The blocker also reduced the blood pressure in the hyperandrogenemic female rats, 17 but not controls, suggesting that the SNS activation was mediated at least in part by activation of the MC4R. These data were interesting to us, as we had previously shown that hypertension in both old and young female SHR was refractory to SHU-9119 blockade despite the fact that the drug reduced blood pressure in old male SHR, 22 just as had been shown previously in young male rats. 20 We have hypothesized that perhaps the presence of androgens increases activation of the MC4R in the PCOS model compared with female SHR. In support of this hypothesis, we found that the expression of the MC4R in the brain of DHT-treated female rats was significantly higher than in control female rats. We are now in the process of inhibiting the androgen receptor in the brain and then giving the MC4R antagonist to determine if our hypothesis is correct.
Role of 20-Hydroxyeicosatetraenoic Acid
Schwartzman and colleagues have studied the effect of increased androgens in 20-hydroxyeicosatetraenoic acid (20-HETE) synthesis and found that testosterone supplements in male animals increases cytochrome P-450 (CYP) 4A u-hydroxylase expression and activity, leading to increased synthesis of 20-HETE in the kidney. 23 We tested the hypothesis that 20-HETE may also contribute to the elevated blood pressure in hyperandrogenemic female rats. 24 We determined that DHT-treatment in female rats increased endogenous 20-HETE levels and u-hydroxylase activity in isolated renal microvessels but not in cerebral vessels. 24 These data are important, as the location of 20-HETE expression in the kidney determines whether it is prohypertensive or antihypertensive. 25 For example, if 20-HETE is present in the renal microvessels, this causes vasoconstriction and increase in GFR, leading to elevated blood pressure. If 20-HETE is present in the tubules of the kidney, it blocks sodium reabsorption and thus is antihypertensive. In addition to the upregulation of 20-HETE and the u-hydroxylase activity in the renal microvessels of DHT-treated female rats, we also found that both 20-HETE and uhydroxylase activity were reduced in renal microsomal preparations (renal tubules) from DHT-treated female rats compared with control female rats. 24 We also found that the CYP4A2 expression was increased by 15-fold and that CYP4A8 was decreased by 50% in kidneys of DHT-treated female rats compared with controls. 24 Using female CYP4A2 -/-rats and SS.BN5 wild type, we found that although androgen treatment increased blood pressure in the wild type female rats, androgens failed to increase blood pressure in the CYP4A2 -/-female rats, 24 supporting the contention that CYP4A2 u-hydroxylase was necessary for androgens to increase blood pressure. As the Dahl saltsensitive (DS) rat is deficient in renal 20-HETE, 26 we also tested whether androgens would increase blood pressure in DS female rats compared with Dahl salt-resistant (DR) rats. We found that although androgens increased blood pressure in DR female rats, androgens failed to increase the blood pressure in DS female rats, 24 again supporting the importance of the 20-HETE in mediating the androgen-mediated elevation in blood pressure in the PCOS model. It does not appear that 20-HETE in the brain plays any role in mediating androgen-dependent sympathetic activity or the MC4R activation in the PCOS model, as androgens had no effect on brain microvessel 20-HETE and actually reduced cerebral vessel u-hydroxylase activity in these studies. 24 Role of the Renin-Angiotensin System Androgens are known to increase intrarenal expression of some of the components of the renin-angiotensin system (RAS). 27, 28 For example, androgens upregulate the synthesis of angiotensinogen and thus could affect renin activity. We have found that chronic DHT in female rats increased mRNA expression of angiotensinogen by 9-fold, increased angiotensin converting enzyme (ACE) mRNA by approximately 50%, and reduced angiotensin AT1 receptor mRNA expression in the cortex. 4 We have not measured ACE or plasma renin activity in our PCOS model, and we have only preliminary data that RAS blockade modestly reduces their blood pressure (Reckelhoff, unpublished data) .
Another mechanism by which the RAS could affect the blood pressure in DHTtreated female rats is via its effect to increase oxidative stress. In our original studies, we found that mRNA expression of some of the submits of NADPH oxidase are increased in the PCOS model. For example, mRNA expression of gp91phox, p22phox, p47phox, and NOX4 were all increased in kidneys of DHT-treated female rats. 4 We have also found that urinary nitrate/nitrite excretiondan index of whole body nitric oxide productiondwas also significantly lower in the DHT-treated female rats, 4 perhaps due to increases in oxidative stress, particularly superoxide. However, the role of oxidative stress in mediating the elevated blood pressure in the PCOS model is not clear, as tempol failed to reduce the blood pressure (Reckelhoff, unpublished data).
POSTMENOPAUSAL HYPER-ANDROGENEMIA AND BLOOD PRESSURE
We have had a longstanding interest in the mechanisms responsible for postmenopausal hypertension. 29 Women with PCOS have increased risk factors for cardiovascular disease, including hypertension, and androgen levels remain elevated in women with PCOS following menopause. 30 However, whether women who have had PCOS throughout their reproductive lives have accelerated cardiovascular disease after menopause compared with their non-PCOS counterparts is not clear. A meta-analysis study published in 2013 showed that although women who had PCOS during their reproductive years continue to have cardiovascular risk factors, such as increased insulin, the majority of these women are not at increased risk for cardiovascular morbidity and mortality compared with women who did not have PCOS. 31 However, the authors point out the limited number of studies performed in women with PCOS who are postmenopausal.
To evaluate whether the rat model of PCOS exhibits increased cardiovascular disease with aging, female rats were treated chronically with DHT from 4 to 5 weeks of age through cessation of estrous cycling to 13 months of age. 32 Plasma DHT levels were 3-fold higher than in age-matched control female rats, and estradiol levels were approximately 10-fold lower. Body weight, visceral adiposity, and subcutaneous adiposity were higher in the PCOS model than the controls. Metabolic syndrome was still present compared with controls, with increases in plasma insulin, glucose, and OGTT. Mean arterial pressure was higher, and heart rate was significantly lower in the PCOS model, suggesting even greater sympathetic activation than in age-matched controls or previously studied young female rats treated with DHT. GFR was slightly lower in the PCOS model than in the control rats at this age, but there was little renal injury.
We allowed the female rats to age further to 22 to 24 months of age. Female Sprague Dawley rats are typically protected from renal injury compared with aging male rats. 33 However, in the chronically DHTtreated female rats, we found they had chronic kidney disease with 60% reductions in GFR and 40% reductions in renal plasma flow. 34 Mean arterial pressure was not dissimilar from the levels found at 13 months, however. The DHT-treated female rats also had higher KIM-1 and proteinuria than the control female rats and lower nitrate/nitrite excretion. The kidneys of the aged PCOS model had significant glomerular sclerosis and interstitial fibrosis. These data suggest that, with advanced aging, women with PCOS may have more chronic kidney disease than women who have not had PCOS. Unfortunately, as mentioned previously, there are few studies in aged women with PCOS, much less women with advanced age. More research is needed to determine if women who have had PCOS during their reproductive years develop a higher incidence of chronic kidney disease with aging.
THE CONSEQUENCES OF ANDROGENS IN TRANSGENDER HUMANS
Few studies have evaluated long-term effects of sex steroids in transgender persons. In meta-analysis studies of transgender people, transgender men (female to male) have increases in plasma endothelin, which could have cardiovascular implications. 35, 36 Some studies have shown that they have increases in blood pressure and LDL with reductions in HDL, but this is not entirely consistent among the studies. It seems to depend on the age of the participants in the studies and how long they have been taking androgen therapy. They also exhibit increases in the incidence of PCOS if their reproductive organs are intact. With regard to blood pressure, most studies show that transsexual men have increases in blood pressure with testosterone supplements.
36,37
THE 4-CORE CHROMOSOME MOUSE AS A MODEL FOR FUTURE STUDIES The 4-core chromosome mouse, in which the Sry gene that determines maleness is on an autosome such that there are XY and XX female mice and XY and XX male mice, could be an important tool in the study of the effects of androgens. 38 In this model, by removing the sex organs, it is possible to separate chromosomal from the sexesteroid-mediated effects. Although most factors studied to date have been found to be sex-steroid mediated, Li and colleagues reported that XX mice have a poorer response to cardiac ischemia-reperfusion injury than do XY animals, a consequence of the number of X chromosomes, not lack of Y chromosomes, and independent of sex steroids. 39 The exploitation of this model may shed more light in the future on the mechanisms responsible for androgenmediated adverse effects on cardiovascular disease in women and elucidate the mechanisms by which androgens are metabolically protective but cardiovascularly detrimental in men.
CONCLUSION
As shown in the Table, from our animal studies it is quite clear than androgens have different effects in male and female animals. Despite the sex differences in response to androgens, both male and female rats become hypertensive with androgen supplements. The implications of these differences are important not only in women who have PCOS but also in transgender men, as it RAS ¼ renin-angiotensin system; TNFa ¼ tumor necrosis factor-alpha.
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appears that the differential responses to androgens persist and do not resolve even after long-term testosterone treatment. Additional animal studies will be necessary to separate the cardiovascular-metabolic consequences of androgens that are chromosomally (genetically) mediated from those that are sexsteroid mediated and provide the potential for additional therapeutic options for hypertension.
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